Subsequently, in 2017, Naito’s group reported the second Dasatinib-derived BCR-ABL PROTAC molecule DAS-IAP (35, Figure 7), which had good activity in inhibiting the growth of CML cells and sustaining anti-proliferation effects (Shimokawa et al., 2017). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.